A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm Phase3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Latest Information Update: 10 Sep 2024
At a glance
- Drugs Tarcocimab tedromer (Primary)
- Indications Diabetic retinopathy
- Focus Registrational; Therapeutic Use
- Acronyms GLOW
- Sponsors Kodiak Sciences
Most Recent Events
- 02 Jun 2024 This trial has been completed in Czech (Global end date: 31 Aug 2023).
- 06 Nov 2023 According to a Kodiak Sciences media release, Primary endpoint (Proportion of eyes improving 2 steps on the ETDRS Diabetic Retinopathy Severity Scale (DRSS)) has been met.
- 06 Nov 2023 According to a Kodiak Sciences media release, data from the study were presented at the American Academy of Ophthalmology